Scailyte reaches USD 8 million in Series A

Founded in 2017, Scailyte is on a mission to advance precision medicine with single-cell omics technologies and proprietary artificial intelligence (AI). The ETH spinoff has developed an AI-powered data analysis platform, ScaiVision, which can analyze millions of individual cells with an unbiased approach, thus identifying the precise molecular profiles (biomarkers) of specific cell types. ScaiVision can then connect these data(sets) with clinical information, including disease diagnosis or treatment response, hereby providing unprecedented insight into a patient’s disease and biology.

By discovering new clinically relevant biomarker signatures, this multimodal platform can accelerate drug development and increase the success rates in clinical trials as well as personalized cancer treatment. So far, ScaiVision’s performance in clinical settings has been tested and demonstrated in CAR-T cell therapies and clinical projects in different disease areas such as endometriosis and solid tumors. Strategic partners such as Nilogen, Volv Global and Sirona DX are collaborating with Scailyte to advance novel and personalized therapies against cancers or rare diseases.

With the additional funding, Scailyte will continue advancing its biomarker technology and expanding its presence in the U.S. market. Peter Nestorov, CEO & Co-founder, shares his excitement, "In the past year, we have gained significant commercial traction, validating the market need for an unbiased and powerful biomarker discovery approach, which delivers reliable and translatable insights from small patient populations." The startup aims to develop more strategic partnerships in the precision oncology space to increase the success rate of novel cancer- and cell-therapies in the clinic, based on reliable and translatable insights from small patient populations.

(Press release / SR)